Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Healthcare Conference
June 16, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference
May 26, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET
|
Neos Therapeutics, Inc.
– Company announces reduction in force to streamline costs and accelerate the path to profitability, particularly in light of the business impact from the COVID-19 pandemic – – Company to host...
Neos Therapeutics to Host First Quarter 2020 Financial and Operating Results Conference Call on May 11th, 2020
May 04, 2020 16:05 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin
April 09, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, April 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics Statement: COVID-19 Update
March 30, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Jerry McLaughlin, President and CEO, made the following statement: We want to share the steps we are taking to ensure healthcare...
Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
March 13, 2020 07:47 ET
|
Neos Therapeutics, Inc.
– Full year 2019 net revenues increased by 29% and operating loss decreased by $33M – – Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end – – NT0502 Phase 1...
Neos Therapeutics to Host Fourth Quarter and Year-End 2019 Financial and Operating Results Conference Call on March 13th, 2020
March 06, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, March 06, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
February 26, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea
January 13, 2020 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...